logo
  

Vanda Settles HETLIOZ Patent Litigation With MSN

Vanda Pharmaceuticals Inc. (VNDA) said that it has reached a License Agreement with MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and Impax Laboratories to settle Vanda's patent litigation against MSN regarding MSN's Abbreviated New Drug Application seeking approval of its generic version of Vanda's HETLIOZ or tasimelteon.

As per the license deal, Vanda granted MSN and Impax a non-exclusive license to manufacture and commercialize MSN's version of HETLIOZ in the U.S. effective March 13, 2035, unless prior to that date Vanda obtains pediatric exclusivity for HETLIOZ, in which case, the license will be effective July 27, 2035. MSN and Impax may enter the market earlier under certain limited circumstances.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Aerospace giant Boeing Co. (BA) on Wednesday reported fourth-quarter net loss attributable to Boeing shareholders of $4.16 billion or $7.02 per share, sharply narrower than $8.44 billion or $14.65 per share in the year-ago quarter. The 787 program recorded $3.5 billion pre-tax non-cash charge; focused... Telecom giant AT&T reported Wednesday a profit for the fourth quarter compared to a loss last year, primarily boosted by continuing customer growth in wireless, fiber and HBO Max, despite a 10 percent drop in revenues. Both adjusted earnings for the quarter and quarterly revenues also topped analysts' expectations. However, the company issued weak earnings and sales growth outlook for fiscal 2022. Bentley Motors, owned by German automaker Volkswagen AG, announced plans to develop its first-ever Battery-Powered Electric Vehicle or BEV in 2025. The British luxury carmaker also plans investment of around 2.5 billion pounds or $3.4 billion in sustainability over the next ten years. The company will develop and build the new vehicles in the UK plant in Crewe.
RELATED NEWS
Follow RTT